Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

4.14
+0.23866.12%
Volume:5.25M
Turnover:22.19M
Market Cap:431.83M
PE:-3.92
High:4.45
Open:3.96
Low:3.95
Close:3.90
52wk High:8.75
52wk Low:2.90
Shares:104.34M
Float Shares:104.00M
Volume Ratio:0.99
T/O Rate:5.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0561
EPS(LYR):-1.3388
ROE:-52.61%
ROA:-30.87%
PB:2.33
PE(LYR):-3.09

Loading ...

Press Release: Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Dow Jones
·
Sep 15

Bitcoin above first major resistance level with ALT coins rallying

Kitco
·
Sep 11

Altimmune Inc. Faces Class Action Lawsuit Over Alleged Securities Fraud by Investors

Reuters
·
Aug 28

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

THOMSON REUTERS
·
Aug 19

Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge

Reuters
·
Aug 19

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Benzinga
·
Aug 14

Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 14

UBS Adjusts Price Target on Altimmune to $24 From $26, Maintains Buy Rating

MT Newswires Live
·
Aug 13

Altimmune Inc : UBS Cuts Target Price to $24 From $26

THOMSON REUTERS
·
Aug 13

Altimmune Q2 FY2025 Earnings Call Transcript

Benzinga
·
Aug 12

Altimmune Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 12

Altimmune Q2 EPS $(0.27) Beats $(0.32) Estimate, Sales $5.000K Beat $560.000 Estimate

Benzinga
·
Aug 12

Altimmune Q2 Revenue USD 5 Thousand VS. Ibes Estimate USD 1.2 Thousand

THOMSON REUTERS
·
Aug 12

Altimmune Q2 Basic EPS USD -0.27

THOMSON REUTERS
·
Aug 12

Altimmune Names Jerry Durso Chair

MT Newswires Live
·
Aug 11

Altimmune Board of Directors Appoints Jerry Durso as Chairman

THOMSON REUTERS
·
Aug 11

Altimmune Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
Aug 08

Immunocore reports second quarter financial results and provides a business update

GlobeNewswire
·
Aug 07

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

GlobeNewswire
·
Aug 07

Altimmune Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
Aug 04